Anna Eva Charlotte Stoelinga (Anna E C Stoelinga)

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Cross Sectional

Top Venues

Journal of translational medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Tamas Pongracz, Maaike Biewenga, Anna Eva Charlotte Stoelinga, Marco René Bladergroen, Simone Nicolardi, Leendert Adrianus Trouw, Dana L E Vergoossen, Noortje de Haan, Bart van Hoek
Autoimmune hepatitis displays distinctively high multi-antennary sialylation on plasma N-glycans compared to other liver diseases. Journal of translational medicine 22 (1) (2024)
Anna Eva Charlotte Stoelinga, Maarten E Tushuizen, Wilbert B van den Hout, Mar D M Rodriguez Girondo, Elsemieke S de Vries, Amar D Levens, Dirk-Jan A R Moes, Tom J G Gevers, Suzanne van der Meer, Hans T Brouwer, Hendrik J M de Jonge, Ynte S de Boer, Ulrich H W Beuers, Adriaan J van der Meer, Aad P van den Berg, Maureen M J Guichelaar, Joost P H Drenth, Bart van Hoek, null null
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial. Trials 25 (1) (2024)
Tamas Pongracz, Maaike Biewenga, Anna Eva Charlotte Stoelinga, Marco René Bladergroen, Simone Nicolardi, Leendert Adrianus Trouw, Dana L E Vergoossen, Noortje de Haan, Bart van Hoek
Autoimmune hepatitis displays distinctively high multi-antennary sialylation on plasma N-glycans compared to other liver diseases. Journal of translational medicine 22 (1) (2024)
Anna Eva Charlotte Stoelinga, Maarten E Tushuizen, Wilbert B van den Hout, Mar D M Rodriguez Girondo, Elsemieke S de Vries, Amar D Levens, Dirk-Jan A R Moes, Tom J G Gevers, Suzanne van der Meer, Hans T Brouwer, Hendrik J M de Jonge, Ynte S de Boer, Ulrich H W Beuers, Adriaan J van der Meer, Aad P van den Berg, Maureen M J Guichelaar, Joost P H Drenth, Bart van Hoek, null null
Tacrolimus versus mycophenolate for AutoImmune hepatitis patients with incompLete response On first-line therapy (TAILOR study): a study protocol for a phase III, open-label, multicentre, randomised controlled trial. Trials 25 (1) (2024)